Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults. (MORA)

A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus MOVIPREP Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

This study evaluates the efficacy, safety and tolerability of NER1006 versus MOVIPREP in adult patients requiring bowel cleansing prior to any procedure that requires a clean bowel, using a 2-Day evening/morning Split-Dosing and 1-Day morning only Split-Dosing regimens. Approximately 810 patients will be randomised with the aim of achieving a minimum of 245 patients in each of the 3 groups.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer; Colorectal Carcinoma; Colon Cleansing
• Intervention / Treatment: Drug: NER1006, 2-Day Split-Dosing; Drug: NER1006,1-Day Morning Split-Dosing; Drug: MOVIPREP, 2-Day Split-Dosing

• Study Type: Interventional
• Enrollment (Actual): 849
• Phase: Phase 3

Contacts and Locations

Study Locations

• Belgium
  • Brugge, Belgium
    • AZ Sint-Lucas
  • Ghent, Belgium
    • UZ Ghent
  • Leuven, Belgium, 3000 Leuven
    • UZ Leuven
  • Liège, Belgium
    • CHC- Clinique Saint-Joseph
• France
  • Bobigny, France
    • Hôpital Avicenne- Service de Gastro-Entérologie
  • Nantes, France
    • Hôpital Hôtel-Dieu
• Germany
  • Essen, Germany
    • Kliniken Essen-Mitte; Abteilung für Gastroenterologie
  • Jena, Germany
    • Klinikum der Friedrich Schiller Universität Jena
  • Ludwigshafen, Germany
    • Praxis für Innere Medizin, Gastroenterologie und Allg. Medizin
• Italy
  • Bologna, Italy
    • A.O.U. di Bologna - Policlinico S. Orsola-Malpighi
  • Como, Italy
    • Ospedale Valduce U.O. Gastroenterologia e Endoscopia
  • Naples, Italy
    • P.O. Maresca OORR Area Vesuviana ASL
  • Pordenone, Italy
    • Centro di Riferimento Oncologico (C.R.O.) S.O.C Gastroenterologia
  • Roma, Italy
    • Pol. Univ. A. Gemelli U.O. di Endoscopia Digestiva Chirurgica
• Poland
  • Białystok, Poland
    • Uniwersytecki Szpital Kliniczny w Bialymstoku
  • Czestochowa, Poland
    • Gabinet Internistyczny dr n. med. Krzysztof Janik
  • Warsaw, Poland
    • Centralny Szpital Kliniczny Ministerstwa Spraw Wewnetrznych
  • Warsaw, Poland
    • Robert Petryka Gabinet Internistyczny
  • Wrocław, Poland
    • Lexmedica Durbajlo Hanna
  • Łódź, Poland
    • NZOZ Centrum Medyczne-Szpital Swietej Rodziny
• Spain
  • Alicante, Spain
    • Hospital General Universitario de Alicante
  • Barcelona, Spain
    • Hospital del Mar
  • Barcelona, Spain
    • Hospital Universitari Germans Trias i Pujol
  • Madrid, Spain
    • Hospital Clínico San Carlos
  • Madrid, Spain
    • Hospital Ramon y Cajal - Ctra. De Colmenar km. 9, 100
• United Kingdom
  • Edinburgh, United Kingdom
    • Lothian Health Board
  • Melrose, United Kingdom
    • Borders General Hospital
  • Shrewsbury, United Kingdom
    • Royal Shrewsbury Hospital
  • Wigan, United Kingdom
    • Royal Albert Edward Infirmary Department

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must provide written informed consent.
• Male and female outpatients and inpatients aged: ≥18 to ≤85 years undergoing a screening, surveillance or diagnostic colonoscopy.
• Females of child-bearing potential must have a negative pregnancy test at Screening and at Visit 2 and must be practising one of the following methods of birth control and agree to continue with the regimen throughout the study period (unless postmenopausal or surgically sterile, or whose sole sexual partner has had a successful vasectomy): Oral, implantable, or injectable contraceptives (for a minimum of three months before study entry) in combination with a condom; Intrauterine device in combination with a condom; Double barrier method (condom* and occlusive cap [diaphragm or cervical/vault caps] with spermicidal foam/gel/film/cream/suppository).
• Willing and able to complete the entire study and to comply with instructions.

Exclusion Criteria:

• Patients with past history within last 12 months or current episode of severe constipation (requiring repeated use of laxatives/enema or physical intervention before resolution), known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
• Patients with ongoing severe acute Inflammatory Bowel Disease.
• Patients who have had previous significant gastrointestinal surgeries, including colonic resection, sub-total colectomy, abdomino-perineal resection, de-functioning colostomy, Hartmann's procedure and de-functioning ileostomy or other similar surgeries involving structure and function of the small or large colon.
• Regular use of laxatives or colon motility altering drugs in the last month (i.e. more than 2-3 times per week) and/or laxative use within 72 hours prior to administration of the preparation.
• Patients with active intestinal bleeding episodes or with a clinically significant low hemoglobin level <9 g/dL for women and <11 g/dL for men at screening.
• Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
• Known phenylketonuria.
• Known hypersensitivity to polyethylene glycols, ascorbic acid and sulfates (not including sulfa-based products) or any other component of the study drug or comparator
• Past history within the last 12 months or evidence of any on-going clinically relevant electrocardiogram (ECG) abnormalities (e.g. arrhythmias).
• History of uncontrolled hypertension with systolic blood pressure >170 mmHg and diastolic blood pressure >100 mmHg.
• Patients with cardiac insufficiency NYHA grades III or IV.
• Patients with severe renal insufficiency (i.e. with GFR, <30 mL/min/1.73m2).
• Patient with serum albumin <3.4 g/dL.
• Patients with liver disease of grades B and C according to the Child Pugh classification.
• Patients suffering from dehydration at screening as evaluated by the Investigator from physical examination and laboratory investigations.
• Patients with clinically significant electrolyte abnormalities, whether pre-existing or noted at screening, such as hypernatremia, hyponatremia, hyperphosphatemia, hypermagnesemia, hypokalemia, hypocalcaemia dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
• Patients with any other clinically significant hematological parameters including coagulation profile at screening.
• Patients with impaired consciousness that might predispose them to pulmonary aspiration.
• Patients undergoing colonoscopy for foreign body removal and/or decompression.
• Patients who are pregnant or lactating, or intending to become pregnant during the study.
• Clinically relevant findings on physical examination based on the Investigator's judgment.
• History of drug or alcohol abuse within the 12 months prior to dosing.
• Concurrent participation in an investigational drug or device study or participation within three months of study entry.
• Patients who are ordered to live in an institution on court or authority order

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Screening
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NER1006, 2-Day Split-Dosing; NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).	Drug: NER1006, 2-Day Split-Dosing; The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
Experimental: NER1006,1-Day Morning Split-Dosing; NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).	Drug: NER1006,1-Day Morning Split-Dosing; The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid. After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid.
Active Comparator: MOVIPREP, 2-Day Split-Dosing; MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).	Drug: MOVIPREP, 2-Day Split-Dosing; The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With Successful Bowel Cleansing (Overall Colon)	The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). A final HCS grading of A, B, C or D was derived. Grades A and B are classified as successful (i.e. all mucosa could be visualized) and C and D are classified as unsuccessful. Comparison of overall success of cleansing with NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.	Up to 2 days (from day of first dosing to day of colonoscopy)
Number of Patients With 'Excellent Plus Good' (Highly Effective) Bowel Cleansing (Colon Ascendens)	The overall quality of bowel cleansing was assessed by a blinded central reader (an experienced and trained colonoscopist) using the segmental scores of the Harefield Cleansing Scale (HCS). Highly effective cleansing in the colon ascendens corresponded to scores 3 (Good) or 4 (Excellent) of the HCS. Adequate plus failure of cleansing corresponded to score 0-2. Comparison of 'Excellent plus good' cleansing of the colon ascendens using NER1006 2-Day and 1-Day versus MOVIPREP was evaluated using a non-inferiority study design.	Up to 2 days (from day of first dosing to day of colonoscopy)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adenoma Detection Rate (Colon Ascendens)	Comparison of the number of patients with at least one adenoma detected in the colon ascendens when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Adenoma detection rate (ADR) defined as the number of patients with at least one adenoma in the colon ascendens.	Up to 2 days (from day of first dosing to day of colonoscopy)
Adenoma Detection Rate (Overall Colon)	Comparison of the number of patients with at least one adenoma detected in the overall colon when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Adenoma detection rate (ADR) defined as the number of patients with at least one adenoma in the overall colon.	Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Colon Ascendens)	Comparison of the number of patients with at least one polyp detected in the colon ascendens when NER1006 2-Day and 1-Day is used for bowel cleansing versus MOVIPREP. Polyp detection rate (PDR) defined as the number of patients with at least one polyp in the colon ascendens.	Up to 2 days (from day of first dosing to day of colonoscopy)
Polyp Detection Rate (Overall Colon)	Comparison of the number of patients with at least one polyp detected in the overall colon when NER1006 is used for bowel cleansing versus number detected when MOVIPREP is used. PDR defined as the number of patients with at least one polyp in the overall colon.	Up to 2 days (from day of first dosing to day of colonoscopy)

Collaborators and Investigators

• Sponsor: Norgine
• Investigators: Principal Investigator: Raf Bisschops, MD, UZ Leuven

Publications and helpful links

General Publications

• Cash BD, Allen C, Poppers DM. Transient alterations in plasma sodium concentrations with NER1006 bowel preparation: an analysis of three phase III, randomized clinical trials. BMC Gastroenterol. 2022 Sep 5;22(1):412. doi: 10.1186/s12876-022-02484-7.
• Bisschops R, Manning J, Clayton LB, Ng Kwet Shing R, Alvarez-Gonzalez M; MORA Study Group. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy. 2019 Jan;51(1):60-72. doi: 10.1055/a-0638-8125. Epub 2018 Jul 19.

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Actual): August 1, 2015
• Study Completion (Actual): August 1, 2015

Study Registration Dates

• First Submitted: October 16, 2014
• First Submitted That Met QC Criteria: October 22, 2014
• First Posted (Estimate): October 23, 2014

Study Record Updates

• Last Update Posted (Actual): May 15, 2018
• Last Update Submitted That Met QC Criteria: April 12, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: NER1006-02/2014 (MORA)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO